DK1345910T3 - Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf - Google Patents

Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf

Info

Publication number: DK1345910T3
Authority: DK; Denmark
Prior art keywords: compounds; preparation; quinazoline derivatives; drugs containing; drugs
Prior art date: 2000-12-20

Application number

DK01271363T

Other languages

English (en)

Inventor

Anke Baum

Frank Himmelsbach

Elke Langkopf

Stefan Blech

Birgit Jung

Flavio Solca

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-20

Filing date

2001-12-12

Publication date

2009-07-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7667887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1345910(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-12-12 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2009-07-20 Application granted granted Critical

2009-07-20 Publication of DK1345910T3 publication Critical patent/DK1345910T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

DK01271363T 2000-12-20 2001-12-12 Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf DK1345910T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10063435A DE10063435A1 (de)	2000-12-20	2000-12-20	Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PCT/EP2001/014569 WO2002050043A1 (de)	2000-12-20	2001-12-12	Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Publications (1)

Publication Number	Publication Date
DK1345910T3 true DK1345910T3 (da)	2009-07-20

Family

ID=7667887

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01271363T DK1345910T3 (da)	2000-12-20	2001-12-12	Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf

Country Status (40)

Country	Link
EP (2)	EP2112140A1 (da)
JP (1)	JP3827641B2 (da)
KR (1)	KR100852102B1 (da)
CN (1)	CN1277822C (da)
AR (1)	AR040524A1 (da)
AT (1)	ATE430136T1 (da)
AU (2)	AU2002219174B2 (da)
BE (1)	BE2014C009I2 (da)
BG (1)	BG66139B1 (da)
BR (1)	BRPI0116266B8 (da)
CA (1)	CA2432428C (da)
CY (2)	CY1109290T1 (da)
CZ (1)	CZ302721B6 (da)
DE (2)	DE10063435A1 (da)
DK (1)	DK1345910T3 (da)
EA (1)	EA006317B1 (da)
EE (1)	EE05244B1 (da)
ES (1)	ES2326617T3 (da)
FR (1)	FR14C0009I2 (da)
HK (1)	HK1060571A1 (da)
HR (1)	HRP20030504B1 (da)
HU (2)	HU228874B1 (da)
IL (2)	IL156277A0 (da)
LT (1)	LTC1345910I2 (da)
LU (1)	LU92370I2 (da)
ME (1)	ME02777B (da)
MX (1)	MXPA03005559A (da)
MY (1)	MY136086A (da)
NO (3)	NO325672B1 (da)
NZ (1)	NZ526918A (da)
PL (1)	PL214798B1 (da)
PT (1)	PT1345910E (da)
RS (1)	RS50860B (da)
SI (1)	SI1345910T1 (da)
SK (1)	SK287573B6 (da)
TW (1)	TWI295992B (da)
UA (1)	UA74614C2 (da)
UY (1)	UY27078A1 (da)
WO (1)	WO2002050043A1 (da)
ZA (1)	ZA200304141B (da)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0201900A3 (en)	1999-06-21	2003-02-28	Boehringer Ingelheim Pharma	Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de) *	2002-02-05	2003-08-07	Boehringer Ingelheim Pharma	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en)	2002-04-19	2004-03-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PE20040945A1 (es) *	2003-02-05	2004-12-14	Warner Lambert Co	Preparacion de quinazolinas substituidas
DE10307165A1 (de) *	2003-02-20	2004-09-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US7223749B2 (en)	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (de) *	2003-07-28	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
WO2005026150A1 (en)	2003-09-16	2005-03-24	Astrazeneca Ab	Quinazoline derivatives as tyrosine kinase inhibitors
US7456189B2 (en)	2003-09-30	2008-11-25	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
CN1972688B (zh) *	2004-05-06	2012-06-27	沃尼尔·朗伯有限责任公司	4-苯胺基-喹唑啉-6-基-酰胺类化合物
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006081741A1 (fr) *	2005-02-05	2006-08-10	Piaoyang Sun	Dérivés de quinazoline ou leurs sels de qualité pharmaceutique, synthèse et applications médicales desdites substances
KR100832594B1 (ko) *	2005-11-08	2008-05-27	한미약품 주식회사	다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
CA2833852C (en) *	2005-11-11	2014-10-21	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
SI1948180T1 (sl)	2005-11-11	2013-06-28	Boehringer Ingelheim International Gmbh	Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
SI1981863T1 (sl)	2006-01-26	2013-01-31	Boehringer Ingelheim International Gmbh	Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
ATE552835T1 (de) *	2006-09-18	2012-04-15	Boehringer Ingelheim Int	Verfahren zur behandlung von tumoren mit egfr- mutationen
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
CA2677336A1 (en)	2007-02-06	2008-08-14	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
DK2245026T3 (da)	2008-02-07	2012-10-15	Boehringer Ingelheim Int	Spirocycliske heterocycler, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
AU2009247782C1 (en)	2008-05-13	2013-09-19	Astrazeneca Ab	Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
UY31867A (es)	2008-06-06	2010-01-29	Boehringer Ingelheim Int	Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
US8426430B2 (en)	2008-06-30	2013-04-23	Hutchison Medipharma Enterprises Limited	Quinazoline derivatives
JP5539351B2 (ja)	2008-08-08	2014-07-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
TWI385174B (zh) *	2008-11-10	2013-02-11	Nat Health Research Institutes	作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物
EP2387401A1 (en)	2009-01-14	2011-11-23	Boehringer Ingelheim International GmbH	Method for treating colorectal cancer
JP2012526767A (ja) *	2009-05-14	2012-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	癌及び線維性疾患の処置における新規な併用療法
WO2010130757A1 (en)	2009-05-14	2010-11-18	Boehringer Ingelheim International Gmbh	New combination therapy in treatment of oncological and fibrotic diseases
PL2451445T3 (pl)	2009-07-06	2019-09-30	Boehringer Ingelheim International Gmbh	Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
US20130012465A1 (en)	2009-12-07	2013-01-10	Boehringer Ingelheim International Gmbh	Bibw 2992 for use in the treatment of triple negative breast cancer
US8735409B2 (en) *	2009-12-21	2014-05-27	Qiang Zhang	Quinazoline derivatives
US20120107304A1 (en)	2010-04-27	2012-05-03	Boehringer Ingelheim International Gmbh	Combination therapy in treatment of oncological and fibrotic diseases
JP2013536244A (ja)	2010-08-26	2013-09-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｅｇｆｒ阻害剤の投与方法
EA024026B1 (ru) *	2010-11-25	2016-08-31	Рациофарм Гмбх	Новые соли и полиморфные формы афатиниба
KR20200003933A (ko)	2011-03-04	2020-01-10	뉴젠 세러퓨틱스 인코포레이티드	알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
CN102918029B (zh) *	2011-05-17	2015-06-17	江苏康缘药业股份有限公司	4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US8828391B2 (en)	2011-05-17	2014-09-09	Boehringer Ingelheim International Gmbh	Method for EGFR directed combination treatment of non-small cell lung cancer
CN102838590B (zh) *	2011-06-21	2014-07-09	苏州迈泰生物技术有限公司	氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
US20150232457A1 (en)	2011-10-06	2015-08-20	Ratiopharm Gmbh	Crystalline forms of afatinib di-maleate
CN103073539B (zh) *	2011-10-26	2016-05-11	齐鲁制药有限公司	4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
EA026353B1 (ru)	2012-01-17	2017-03-31	Астеллас Фарма Инк.	Соединение пиразинкарбоксамида
CN103772380A (zh) *	2012-10-23	2014-05-07	杨子娇	一类治疗房角狭窄的化合物及其用途
US20150368230A1 (en)	2013-02-01	2015-12-24	Boehringer Ingelheim International Gmbh	Radiolabeled quinazoline derivatives
US20140303098A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
SI2986304T1 (sl)	2013-04-18	2022-04-29	Boehringer Ingelheim International Gmbh	Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
WO2014180271A1 (zh) *	2013-05-10	2014-11-13	苏州明锐医药科技有限公司	阿法替尼及其中间体的制备方法
CN103254183B (zh) *	2013-05-10	2015-11-11	苏州明锐医药科技有限公司	阿法替尼的制备方法
CN103254182A (zh) *	2013-05-10	2013-08-21	苏州明锐医药科技有限公司	一种阿法替尼的制备方法
CN103242303B (zh) *	2013-05-16	2015-03-25	苏州明锐医药科技有限公司	阿法替尼的制备方法
WO2014183560A1 (zh) *	2013-05-16	2014-11-20	苏州明锐医药科技有限公司	阿法替尼及其中间体的制备方法
CN104513229A (zh) *	2013-09-28	2015-04-15	正大天晴药业集团股份有限公司	喹唑啉衍生物及其制备方法
CN103755688B (zh) *	2013-12-24	2015-11-18	江苏奥赛康药业股份有限公司	一种阿法替尼化合物的制备方法
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EP3089976B1 (en)	2014-01-02	2019-08-14	Teva Pharmaceuticals International GmbH	Crystalline forms of afatinib dimaleate
CN105315263B (zh) *	2014-07-30	2018-11-27	正大天晴药业集团股份有限公司	阿法替尼中间体的合成方法
EP3023421A1 (en)	2014-11-21	2016-05-25	Sandoz Ag	Crystalline forms of afatinib dimaleate
CN105801568B (zh)	2015-01-15	2019-07-30	杭州普晒医药科技有限公司	阿法替尼一马来酸盐晶型及其制备方法和药物组合物
WO2016150340A1 (zh) *	2015-03-20	2016-09-29	正大天晴药业集团股份有限公司	喹唑啉衍生物的盐及其制备方法
CN105175400B (zh) *	2015-09-29	2018-04-10	河北神威药业有限公司	一种阿法替尼中间体的制备方法
WO2017141271A1 (en) *	2016-02-17	2017-08-24	Sun Pharmaceutical Industries Ltd.	Stable pharmaceutical composition of afatinib
CN106442793B (zh) *	2016-10-21	2019-05-24	河北神威药业有限公司	一种制备阿法替尼的中间体及其对映异构体的检测方法
EP3538107A1 (en)	2016-11-10	2019-09-18	Boehringer Ingelheim International GmbH	Pharmaceutical composition, methods for treating and uses thereof
TWI808958B (zh)	2017-01-25	2023-07-21	美商特普醫葯公司	涉及二芳基巨環化合物之組合療法
US11708335B2 (en)	2017-12-18	2023-07-25	Sterngreene, Inc.	Pyrimidine compounds useful as tyrosine kinase inhibitors
CN110437163A (zh) *	2018-05-03	2019-11-12	斯特恩格林公司	作为酪氨酸激酶抑制剂的嘧啶类化合物
CA3113241A1 (en)	2018-09-25	2020-04-02	Black Diamond Therapeutics, Inc.	Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
CN109265449B (zh) *	2018-11-07	2021-11-23	沈阳工业大学	Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
US20220040324A1 (en)	2018-12-21	2022-02-10	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
CN109824657A (zh) *	2019-03-26	2019-05-31	石药集团中奇制药技术（石家庄）有限公司	一种二马来酸阿法替尼新晶型及其制备方法和应用
CN110590682A (zh) *	2019-10-14	2019-12-20	重庆医科大学	一种制备阿法替尼杂质的方法以及制备的杂质
US20210161897A1 (en)	2019-11-12	2021-06-03	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
MX2022008874A (es)	2020-01-20	2022-08-11	Astrazeneca Ab	Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
US20210369709A1 (en)	2020-05-27	2021-12-02	Astrazeneca Ab	EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TWI847289B (zh) *	2021-09-30	2024-07-01	大陸商北京賽特明強醫藥科技有限公司	喹唑啉類化合物、組合物及其應用
WO2023187037A1 (en)	2022-03-31	2023-10-05	Astrazeneca Ab	Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023209084A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20240116926A1 (en)	2022-04-28	2024-04-11	Astrazeneca Ab	Heteroaromatic compounds
WO2023209090A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209088A1 (en)	2022-04-28	2023-11-02	Astrazeneca Ab	Bicyclic heteroaromatic compounds and their use in the treatment of cancer
KR20250029133A (ko)	2022-06-27	2025-03-04	아스트라제네카 아베	암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6344459B1 (en) *	1996-04-12	2002-02-05	Warner-Lambert Company	Irreversible inhibitors of tyrosine kinases
ZA986732B (en) *	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) *	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitors of tyrosine kinases
DE19911366A1 (de) *	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
IL144143A0 (en) *	1999-02-27	2002-05-23	Boehringer Ingelheim Pharma	4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
DE19908567A1 (de) *	1999-02-27	2000-08-31	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911509A1 (de) *	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HUP0201900A3 (en) *	1999-06-21	2003-02-28	Boehringer Ingelheim Pharma	Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof
EP1280798B1 (de) *	2000-04-08	2007-01-03	Boehringer Ingelheim Pharma GmbH & Co.KG	Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

2000
- 2000-12-20 DE DE10063435A patent/DE10063435A1/de not_active Withdrawn
2001
- 2001-12-12 CN CNB018208665A patent/CN1277822C/zh not_active Expired - Lifetime
- 2001-12-12 EP EP09158964A patent/EP2112140A1/de not_active Withdrawn
- 2001-12-12 SI SI200130916T patent/SI1345910T1/sl unknown
- 2001-12-12 BR BRPI0116266A patent/BRPI0116266B8/pt not_active IP Right Cessation
- 2001-12-12 NZ NZ526918A patent/NZ526918A/en not_active IP Right Cessation
- 2001-12-12 RS YUP-496/03A patent/RS50860B/sr unknown
- 2001-12-12 PL PL361798A patent/PL214798B1/pl unknown
- 2001-12-12 ES ES01271363T patent/ES2326617T3/es not_active Expired - Lifetime
- 2001-12-12 JP JP2002551540A patent/JP3827641B2/ja not_active Expired - Lifetime
- 2001-12-12 UA UA2003076821A patent/UA74614C2/uk unknown
- 2001-12-12 KR KR1020037008246A patent/KR100852102B1/ko not_active Expired - Lifetime
- 2001-12-12 AU AU2002219174A patent/AU2002219174B2/en active Active
- 2001-12-12 DK DK01271363T patent/DK1345910T3/da active
- 2001-12-12 WO PCT/EP2001/014569 patent/WO2002050043A1/de active Application Filing
- 2001-12-12 CA CA002432428A patent/CA2432428C/en not_active Expired - Lifetime
- 2001-12-12 EA EA200300671A patent/EA006317B1/ru not_active IP Right Cessation
- 2001-12-12 PT PT01271363T patent/PT1345910E/pt unknown
- 2001-12-12 CZ CZ20031930A patent/CZ302721B6/cs not_active IP Right Cessation
- 2001-12-12 ME MEP-2008-595A patent/ME02777B/me unknown
- 2001-12-12 DE DE50114874T patent/DE50114874D1/de not_active Expired - Lifetime
- 2001-12-12 HU HU0301852A patent/HU228874B1/hu active Protection Beyond IP Right Term
- 2001-12-12 AT AT01271363T patent/ATE430136T1/de active
- 2001-12-12 EP EP01271363.2A patent/EP1345910B9/de not_active Expired - Lifetime
- 2001-12-12 EE EEP200300300A patent/EE05244B1/xx active Protection Beyond IP Right Term
- 2001-12-12 AU AU1917402A patent/AU1917402A/xx active Pending
- 2001-12-12 IL IL15627701A patent/IL156277A0/xx unknown
- 2001-12-12 SK SK771-2003A patent/SK287573B6/sk not_active IP Right Cessation
- 2001-12-12 MX MXPA03005559A patent/MXPA03005559A/es active IP Right Grant
- 2001-12-17 UY UY27078A patent/UY27078A1/es not_active Application Discontinuation
- 2001-12-19 TW TW090131520A patent/TWI295992B/zh active
- 2001-12-19 AR AR20010105883A patent/AR040524A1/es active Pending
- 2001-12-19 MY MYPI20015767A patent/MY136086A/en unknown
2003
- 2003-05-28 ZA ZA200304141A patent/ZA200304141B/en unknown
- 2003-06-03 IL IL156277A patent/IL156277A/en active Protection Beyond IP Right Term
- 2003-06-16 NO NO20032726A patent/NO325672B1/no active Protection Beyond IP Right Term
- 2003-06-18 HR HR20030504A patent/HRP20030504B1/xx not_active IP Right Cessation
- 2003-06-19 BG BG107929A patent/BG66139B1/bg active Active
2004
- 2004-05-20 HK HK04103590A patent/HK1060571A1/xx not_active IP Right Cessation
2009
- 2009-07-23 CY CY20091100793T patent/CY1109290T1/el unknown
2014
- 2014-01-30 FR FR14C0009C patent/FR14C0009I2/fr active Active
- 2014-01-31 LU LU92370C patent/LU92370I2/fr unknown
- 2014-02-06 LT LTPA2014005C patent/LTC1345910I2/lt unknown
- 2014-02-11 NO NO2014003C patent/NO2014003I2/no not_active IP Right Cessation
- 2014-02-12 HU HUS1400005C patent/HUS1400005I1/hu unknown
- 2014-02-12 CY CY2014008C patent/CY2014008I2/el unknown
- 2014-02-18 BE BE2014C009C patent/BE2014C009I2/fr unknown
2022
- 2022-07-01 NO NO2022028C patent/NO2022028I1/no unknown

Also Published As

Publication number	Publication date
ES2326617T9 (es)	2014-09-10
LU92370I2 (fr)	2014-03-31
CY2014008I2 (el)	2015-12-09
LTPA2014005I1 (lt)	2022-05-25
LU92370I9 (da)	2019-01-17
MEP59508A (en)	2011-05-10
RS50860B (sr)	2010-08-31
CZ302721B6 (cs)	2011-09-21
DE50114874D1 (de)	2009-06-10
DE10063435A1 (de)	2002-07-04
BG66139B1 (bg)	2011-07-29
EE05244B1 (et)	2009-12-15
WO2002050043A1 (de)	2002-06-27
EA006317B1 (ru)	2005-10-27
UY27078A1 (es)	2002-07-31
BRPI0116266B8 (pt)	2021-07-27
NO20032726L (no)	2003-06-16
BG107929A (bg)	2005-01-31
EP1345910B9 (de)	2014-06-04
UA74614C2 (en)	2006-01-16
HUS1400005I1 (hu)	2017-08-28
EP1345910B1 (de)	2009-04-29
NO20032726D0 (no)	2003-06-16
CZ20031930A3 (cs)	2003-10-15
FR14C0009I1 (fr)	2014-03-07
AU1917402A (en)	2002-07-01
AU2002219174B2 (en)	2007-09-06
NO2014003I2 (no)	2015-10-19
IL156277A (en)	2009-12-24
SK287573B6 (sk)	2011-03-04
PT1345910E (pt)	2009-07-14
ME02777B (me)	2011-10-10
KR100852102B1 (ko)	2008-08-13
HUP0301852A3 (en)	2008-03-28
CA2432428A1 (en)	2002-06-27
PL361798A1 (en)	2004-10-04
NO2014003I1 (no)	2014-06-02
ATE430136T1 (de)	2009-05-15
CY2014008I1 (el)	2014-07-02
PL214798B1 (pl)	2013-09-30
HRP20030504B1 (en)	2011-09-30
HUP0301852A2 (hu)	2003-09-29
HK1060571A1 (en)	2004-08-13
KR20030071787A (ko)	2003-09-06
JP3827641B2 (ja)	2006-09-27
EE200300300A (et)	2003-10-15
BE2014C009I2 (da)	2021-02-04
HRP20030504A2 (en)	2005-06-30
EP1345910A1 (de)	2003-09-24
MXPA03005559A (es)	2004-10-14
EA200300671A1 (ru)	2004-06-24
SI1345910T1 (sl)	2009-08-31
BR0116266A (pt)	2004-02-17
YU49603A (sh)	2006-05-25
TWI295992B (en)	2008-04-21
EP2112140A1 (de)	2009-10-28
LTC1345910I2 (lt)	2022-06-10
SK7712003A3 (en)	2003-10-07
NO2022028I1 (no)	2022-07-01
CA2432428C (en)	2009-09-01
FR14C0009I2 (fr)	2014-11-14
CN1277822C (zh)	2006-10-04
CN1481370A (zh)	2004-03-10
HU228874B1 (en)	2013-06-28
ES2326617T3 (es)	2009-10-16
JP2004516283A (ja)	2004-06-03
IL156277A0 (en)	2004-01-04
MY136086A (en)	2008-08-29
NO325672B1 (no)	2008-07-07
CY1109290T1 (el)	2014-07-02
BRPI0116266B1 (pt)	2017-10-31
NZ526918A (en)	2006-11-30
AR040524A1 (es)	2005-04-13
ZA200304141B (en)	2004-04-15

Publication	Publication Date	Title
DK1345910T3 (da)	2009-07-20	Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf
NO20024175D0 (no)	2002-09-02	Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
NO20032733L (no)	2003-08-14	Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
DK1180518T3 (da)	2007-05-21	5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK1294682T3 (da)	2004-08-02	Acylphenylurinstofderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
NO20014013D0 (no)	2001-08-17	16-halogenepotilonderivater, fremgangsmater for fremstilling av dem og deres farmasoytiske anvendelse
NO20011216L (no)	2001-05-09	Azetidinderivater, deres fremstilling og medikamenter inneholdende forbindelsene
NO20014603L (no)	2001-11-26	Tienopyrimidinforbindelser, deres fremstilling og anvendelse
IS6310A (is)	2002-03-19	Kínasólínafleiður til lækninga
DK1218341T3 (da)	2005-12-12	Sulfonylcarboxamid-derivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
NO20015113L (no)	2001-12-19	Nye forbindelser, deres fremstilling og anvendelse
NO20024742L (no)	2002-11-25	Heterocykliske forbindelser, deres fremstilling og anvendelse
DK1083171T3 (da)	2004-08-09	Pyrazolinderivater, deres fremstilling og anvendelse som medikamenter
MXPA03000873A (es)	2003-06-06	Derivados de quinazolina, medicamentos que contienen estos compuestos, su uso y metodos para la produccion de los mismos.
DK1381605T3 (da)	2005-05-09	Mercaptoacetylamidderivater, en fremgangsmåde til deres fremstilling og deres anvendelse
NO20016038D0 (no)	2001-12-10	Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme
NO20031273L (no)	2003-05-14	Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
DK1674456T3 (da)	2008-10-27	Nye 1,4-benzothiazepin-1,1-dioxid-derivater med forbedrede egenskaber, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
DK1098891T3 (da)	2005-12-12	Polycycliske thiazolidin-2-yliden-aminer, fremgangsmåde til fremstilling deraf og deres anvendelse som lægemidler
DK1118610T3 (da)	2002-12-16	Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne
NO20033120L (no)	2003-09-11	2-arylimino-2,3-dihydrotiazolderivater, fremgangsmåter for fremstilling derav og terapeutisk anvendelse derav
DK1086077T3 (da)	2004-08-02	Hidtil ukendte antiestrogener, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
DK1341758T3 (da)	2006-10-30	Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
DK1157020T3 (da)	2003-01-27	Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-2-benzazocin-10-oler, fremgangsmåder til deres fremstilling og deres anvendelse som lægemiddel
DK1157014T3 (da)	2005-12-27	Polycykliske 2-amino-dihydrothiazolsystemer, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler